Lyell Immunopharma announced new clinical data Tuesday from a Phase I/II trial of its dual-targeted CD19/CD20 CAR T-cell therapy for relapsed or refractory large B-cell lymphoma. The company ...

Some cancers and chronic inflammatory diseases are treated with immunotherapies. These stimulate the patient's immune system ...

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to ...

Despite advances, the roles of genetics and microenvironment in CLL are not fully understood, and curative treatments may hinge on a dual approach targeting both.

Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer ...

In the field of cancer immunotherapy, unconventional T cells (UCTs) and Chimeric Antigen Receptor (CAR) T cells have emerged as promising areas of research ...

Analysis revealed that patients with T-cell exhausted archetype tumors had significantly higher rates of progressive disease ...